Delta, Kelowna, BC - October 15, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,
www.potcasts.ca release today's edition of its series,
Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: TSX: $APH.TO, CSE: $TER.C, CSE: $MWM.C, NASDAQ: $CRON, CSE: $CANA.C, CSE: $MTEC.C
Today's podcast overview/transcript:
*All news sourced from company press releases
Good afternoon and welcome to another Investorideas.com Potcast - following Cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today we will be looking at announcements from TerrAscend Corp. trading on the CSE as TER, Aphria Inc. trading on the TSX as APH, Micron Waste Technologies Inc. trading on the CSE as MWM, Cronos Group Inc. trading on the NASDAQ and TSX as CRON, CANNAMERICA BRANDS CORP. trading on the CSE as CANA and Cannvas MedTech Inc. trading on the CSE as MTEC.
TerrAscend Corp., today announced that its subsidiary TerrAscend Canada Inc. has entered into a multi-year cultivation agreement with PharmHouse Inc., a joint venture between Canopy Rivers Inc. (TSXV: RIV) and the principals and operators of a leading North American greenhouse produce company.
Under the terms of the agreement, PharmHouse will grow and supply cannabis to TerrAscend Canada from an existing 1.3 million square foot greenhouse, located in Leamington, Ontario. Once fully licensed, the production of flower, trim and clones from 20% of the dedicated flowering space at the Facility will be made available to TerrAscend Canada.
TerrAscend Canada may provide proprietary genetic strains to PharmHouse and help oversee production in conjunction with their operators and quality assurance professionals. Cultivation is anticipated to commence in 2019, subject to receipt by PharmHouse of all applicable regulatory licenses and approvals.
Aphria Inc. today announced that it has completed its first shipment of cannabis oil to its Argentina-based subsidiary ABP, S.A., a pharmaceutical import and distribution company. In accordance with a previously announced supply agreement, the Company delivered 1,500 bottles of Aphria's renowned Rideau CBD oil, which were provided to Hospital de Pediatria Garrahan, a leading pediatric hospital located in Buenos Aires, for use in a clinical study focused on treating refractory epilepsy in children.
Aphria acquired ABP last month when the Company closed its acquisition of LATAM Holdings Inc., expanding the Company's global footprint to include a leading presence in Latin America and the Caribbean. "Argentina will play a foundational role as Aphria cements its leadership in medical cannabis throughout the region," said Vic Neufeld, Chief Executive Officer of Aphria. "Aphria and ABP, in close partnership with the Argentinean government, continue to advance opportunities for medical cannabis in the country, including the potential for in-country cultivation. We are also proud to support the critical and necessary research being undertaken by Hospital Garrahan on the treatment of refractory epilepsy in children with our Rideau CBD oil."
As a well-established and successful pharmaceutical import and distribution company, ABP was granted the first permit issued by the Argentina Ministry of Health for the import of pharmaceutical-grade medical cannabis. The Argentinean Company has been forging a reputation as a champion for the research and clinical study of medical cannabis, including through its partnership with the Hospital, one of the most recognized and credible medical institutions in South America.
The clinical study, which involves 100 patients and will be conducted over 2.5 years, will be one of the foundational global scientific and medical studies of its kind focused on treating refractory epilepsy in children. Medical researchers will conduct a pharmacokinetics study of the Rideau product, which will help optimize the ideal dosage in future patients. Top neurologists and pediatric specialists from around the country will participate and, with the support of ABP and Aphria, will receive training and support to be able to train and educate a network of doctors throughout Argentina.
Micron Waste Technologies Inc., a developer of proprietary digester solutions for the treatment of organic waste, today announced that it has partnered with Quest Resource Management Group LLC, a fully owned subsidiary of Quest Resource Holding Corporation (NASDAQ: QRHC), a leader in environmental reuse, recycling, and disposal services, to market and distribute Micron's proprietary Cannavore™ cannabis waste processing systems in the United States.
"Quest operates in all 50 states and provides custom, innovative waste management solutions to a wide range of industries," said Micron President Alfred Wong. "With its strong market positioning, Quest will help accelerate the entry of Micron's leading cannabis waste management technology into the U.S. and capitalize on the expanding American cannabis cultivation market."
The U.S. cannabis industry is rapidly growing, with retail sales projected to reach an estimated $5.1 - $6.1 billion dollars in 2018. By 2020, overall retail sales are projected to reach between $11.9 and $17.1 billion dollars, with $47 billion in sales projected within a decade. The Micron-Quest partnership offers cannabis growers a regulatory-compliant, environmentally-sound alterative to process the production by-product - thousands of tons of pharmaceutical-laden cannabis waste.
The Micron Cannavore was designed to meet the specifications of Aurora Cannabis Inc. ("Aurora")(TSX:ACB), per a collaboration announced in December 2017, for a clean technology solution to process organic waste generated from the growth and cultivation of cannabis, while mitigating concerns about the potential environmental impact.
The industrial-grade Cannavore pulverizes and renders cannabis waste in combination with a proprietary blend of microbes and enzymes designed and developed by Micron. Importantly, as part of Micron's full-system waste treatment platform, effluent from the digester is further treated to derive clean greywater which can be re-used in growing operations. Alternatively, the treated regulatory-compliant greywater from the Cannavore, which exceeds municipal discharge standards, can be safely discharged. Active pharmaceutical ingredients (APIs) in cannabis waste are further biologically treated via a proprietary process to denature cannabinoids present, keeping them out of watersheds, preventing bio-accumulation. Being an aerobic process, it does not emit methane. On-site processing eliminates need for conventional waste methods such as trucking, landfilling and incineration.
Cronos Group Inc., announced today that it has entered into a sponsored research agreement with the Technion Research and Development Foundation of the Technion - Israel Institute of Technology ("Technion") to explore the use of cannabinoids and their role in regulating skin health and skin disorders. The preclinical studies will be conducted by Technion over a three-year period and will focus on three skin conditions: acne, psoriasis and skin repair.
"We believe that the potential applications of cannabinoids to regulate skin health and treat skin disorders are vast, and we are excited to begin exploring these applications through our partnership with Technion," said Mike Gorenstein, CEO of Cronos Group. "Using rigorous data to develop efficacious topical and transdermal formulations will be key to creating differentiated products that provide quality treatments to our consumers and strengthen our brand portfolio."
CANNAMERICA BRANDS CORP., a cannabis branding, licensing and intellectual property company with a portfolio of premium cannabis brands in the United States, began trading today on the Canadian Securities Exchange ("CSE") under the symbol "CANA".
"CannAmerica is excited to achieve this milestone as we work toward expanding our brands into new markets in the U.S. cannabis sector, and beyond," said Dan Anglin, CannAmerica Co-Founder and CEO. "Today's announcement is a significant landmark for CannAmerica and the direct prospectus listing provides investors with access to a new player in this emerging industry. We have multi-state licenses who benefit from a recognized brand, as well as the proprietary formulas, recipes, intellectual property, ingredients, packaging solutions, and trade secrets for creating premium cannabis products."
CannAmerica has brand licensing agreements in the states of Colorado, Nevada and Maryland, and plans to expand to additional U.S. states and internationally, as regulations permit.
The Company's flagship edible gummy brand, CannAmerica, is currently sold in U.S. dispensaries with over 12 million state approved gummies sold in the Colorado market alone, since launching in 2016.
CannAmerica has successfully raised approximately $5.4 million to date via non-brokered private placements, and plans to expand its existing brand portfolio via new license agreements in several new and important U.S. states, including California, in the next six months. The Company is also targeting the acquisition of other well established and/or new consumer cannabis brands with high potential for growth and strong brand awareness in exchange for a royalty on gross sales. These efforts will be a catalyst in the Company's growth strategy and will diversify revenue streams.
Cannvas MedTech Inc., a leading business technology company in the cannabis space, announced its intent, operating under its newly-formed Cannvas Cannabis Acquisitions brand, to create a network of high-tech learning and fulfillment centres across Canada, improving accessibility to free and unbiased education about the potential benefits of medical and adult-use cannabis while providing curious consumers with on-site retail options from leading cannabis brands. Operating under the brand Cannvas Marché, each location will feature on-site medical and educational staff, digital learning resources and a fulfillment program, with the first centre expected to open in Toronto in early 2019.
Potcasts is now a certified word Trademark on the blockchain through Cognate, Inc. CM Certification
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, iHeartradio, Spreaker and Tunein.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Subscribe to the new cannabis podcast series:
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Get the cannabis/hemp stock directory as an Investor ideas member, plus get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the Move. Learn more https://www.investorideas.com/membership/ Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles ,
podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily
Crypto Corner and Podcast,
Play by Play sports and stock news column,
Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column and the Cleantech and Climate Change Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp. Learn more about Investor ideas podcast and news publication services and costs
https://www.investorideas.com/News-Upload/ Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
